What are the common and serious side effects of acamprosate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Acamprosate Side Effects

Acamprosate is generally well-tolerated with diarrhea being the most common side effect, occurring in approximately 11% more patients than placebo, though it has no reported hepatotoxicity and does not require hepatic metabolism. 1

Common Side Effects

The most frequently reported adverse effects occurring at ≥3% and greater than placebo include 1:

Gastrointestinal:

  • Diarrhea (most common, leading to discontinuation in 2% vs 0.7% placebo)
  • Nausea
  • Flatulence
  • Anorexia

Neuropsychiatric:

  • Anxiety
  • Depression
  • Dizziness
  • Insomnia
  • Paresthesia
  • Dry mouth

Dermatologic:

  • Pruritus
  • Sweating

General:

  • Asthenia (weakness)
  • Accidental injury
  • Pain
  • Headache

Serious Adverse Effects

Suicidality and Depression

Acamprosate carries an FDA warning for increased suicidal events compared to placebo (1.4% vs 0.5% in studies ≤6 months; 2.4% vs 0.8% in year-long studies). 1 Completed suicides occurred in 0.13% of acamprosate patients versus 0.10% of placebo patients. While many events occurred during alcohol relapse, patients require monitoring for depression and suicidal ideation, with families/caregivers alerted to watch for these symptoms. 1

Rare Adverse Effects

  • Extrapyramidal symptoms: One case report documented severe extrapyramidal symptoms in an elderly patient, potentially related to acamprosate's effects on dopamine via glutamatergic mechanisms 2
  • Syncope: A case report suggests possible acamprosate-induced syncope in an elderly patient, though causality remains uncertain 3
  • Acute kidney failure: Listed as a clinically significant serious adverse reaction 1

Discontinuation Rates

In placebo-controlled trials ≤6 months, 8% of acamprosate patients discontinued due to adverse events versus 6% on placebo. In longer studies, discontinuation rates were equal at 7% for both groups. 1 Only diarrhea accounted for >1% of discontinuations.

Safety in Special Populations

Hepatic Disease

A critical advantage of acamprosate is its lack of hepatic metabolism and absence of reported hepatotoxicity. 4 Multiple guidelines confirm that liver disease does not change acamprosate indications or dosing 5, making it particularly suitable for alcohol-associated liver disease patients. A phase 2 trial in patients with alcohol-associated liver disease (including those with MELD-Na ≥20) found no significant adverse events or worsening liver disease. 6

Renal Impairment

Acamprosate is contraindicated in severe renal impairment (CrCl ≤30 mL/min) and requires dose reduction in moderate impairment (CrCl 30-50 mL/min). 1 The drug undergoes renal excretion without metabolism. 4

Clinical Context

The overall adverse effect profile is mild and transient in most cases. 7, 8 Gastrointestinal effects, particularly diarrhea, typically occur early in treatment. 7 Importantly, acamprosate does not eliminate or diminish alcohol withdrawal symptoms 1, does not potentiate alcohol's toxic effects 8, and has no abuse potential. 8

The safety profile remains favorable compared to alternatives like naltrexone (which causes hepatotoxicity and is contraindicated in liver disease) and disulfiram (also hepatotoxic). 4, 9, 4 This makes acamprosate a preferred first-line option for patients with alcohol-associated liver disease requiring pharmacotherapy for relapse prevention.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.